<div class="headers"><div>Figure 2 Rate ratios and 95% con<U+FB01>dence intervals for reduction of moderate or severe COPD exacerbations in the ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting b2-agonist.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>16(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 2 Rate ratios and 95% con<U+FB01>dence intervals for reduction of moderate or severe COPD exacerbations in the ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting b2-agonist.</p></td>
</tr>
</tbody>
</table>
